Society on Sarcopenia, Cachexia and Wasting Disorders

Add links
From Wikipedia, the free encyclopedia

Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is an international and multidisciplinary non-profit organization, created in 2008 that focuses on cachexia[1] and sarcopenia.[2] As they are often under-diagnosed, patient groups aim to improve their awareness.[3] Cachexia has been coined the "last illness"[4] and is sometimes called "body wasting".[5] The prevalence of cachexia ranges from 5–15% in end-stage chronic heart failure to 50–80% in advanced malignant cancer.[6] It is estimated that 5 Million Americans have the condition and cachexia frequently occurs in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis.[7] Mortality rates of cachexia patients range from 15 to 25% per year in severe COPD, 20–40% per year in patients with chronic heart failure or chronic kidney disease, to 20–80% per year in cancer cachexia.[8] The SCWD was founded in 2008 on the initiative of Prof. Stefan D. Anker[9] in Germany and Dr. John E. Morley[10] in the US. It is made up of an international and multidisciplinary group of healthcare professionals in the fields of sarcopenia, cachexia and muscle wasting.[11] As of 2018, the society had 150 members.[1]

The purpose and objectives of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) are to:

  • Improve the understanding, diagnosis and treatment of skeletal muscle wasting in various disease conditions and aging[12]
  • Educate healthcare professionals
  • Form partnerships with other professional societies[13]

Legal Structure and Board[edit]

The SCWD is a non-profit scientific organization (501 c3)[14] registered in the United States of America and Switzerland. The president is Prof. Stefan Anker, Germany who is also vice-president of the European Society of Cardiology,[15] the vice-president is Dr. John Morley, USA and the treasurer is Prof. Andrew J. Coats, United Kingdom who particularly investigated cardiac cachexia at an early stage.[16]
The Board consists of:
Stefan D. Anker (President[17]) – Berlin, Germany
Josep M. Argiles – Barcelona, Spain
Vickie E. Baracos – Edmonton, Canada
Andrew J. S. Coats (Treasurer) – Norwich, UK
Wolfram Doehner – Berlin, Germany
William J. Evans[18] – Duke University, US
Luigi Ferrucci[19] – Baltimore, US
David J. Glass – Boston, US
Akio Inui – Kobe, Japan
Aminah Jatoi – Rochester, US
Kamyar Kalantar-Zadeh – Los Angeles, US
John E. Morley (vice-president) – St. Louis, US
Filippo Rossi-Fanelli – Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany

Prof Ken Fearon was a board member until he died in September 2016.[20] He received the Hippocrates Award from the Society.[21] Professor Fearon was particularly involved in cancer cachexia: leading an international consensus.[22]

Educational initiatives[edit]

Conferences[edit]

Since 2000 the SCWD has organized several international conferences.[23][24] In December 2009, the 5th Cachexia conference[25] took place in Barcelona, Spain. In 2011, the 7th conference took place in Italy.[26] One of them took place in Kobe, Japan.[27] These conferences took place every two years until 2015, when in Paris[28] it was decided to organize the conferences annually instead.[29] The location of the 2016 congress is Berlin on 10–11 December 2016.[30] The programme includes a statistical seminar, a mentor or career session and sessions on cachexia, sarcopenia and muscle wasting.[31]

It addresses frailty, sarcopenia and cachexia resulting from the following diseases or chronic conditions: Cancer, Cardiovascular Disease, Death, Dying & Grief, Dementia/Alzheimer's Disease, Diabetes, Heart Failure and Ageing.[32] Update on Anabolic and Related Therapies are also provided.[33] Results of clinical trials are also presented, such as data from a Phase II clinical trial of MT-102 in cancer-related cachexia presented in Kobe in 2013.[34] The latest conference took place in Maastricht in 2018.[2] In 2019, the international conference will take place in Berlin. [3]

Target audience: Internists, Oncologists, Geriatricians, Cardiologists, Nephrologists, Palliative care specialists, Nurse Practitioners and Primary Care Providers.

A charity dinner is sometimes organised during SCWD conferences such as in 2011 in Milan with the participation of Lisa Niemi.[35]

Posters: each meeting features 120-200 posters.[36]

The SCWD releases regular highlights of its meetings.[37]

Consensus meetings[edit]

Since 2006, the SCWD has also organized several consensus meetings to address issues related to the definition of cachexia, sarcopenia[38] as well the regulatory pathways for treatment development in cachexia, sarcopenia and the syndrome of muscle wasting.[39]
The major objective was to bring together a multi-disciplinary team of experts in order to develop, as a united body, a consensus of statements[40] based on the following topics:

  • Definitions of Cachexia, Sarcopenia[41] and Frailty with a proposal for an overall disease classification system of "Muscle Wasting Syndromes" as framework of reference.
  • Classification.[42]
  • Body composition assessment.
  • End-points in clinical trials, including Patient-reported outcomes.
  • Nutrition.[43]
  • Endpoint in clinical trials: strengths and weaknesses.
  • What constitutes clinically meaningful change.
  • New regulatory pathways.

This consensus gathered together about 30 international scientists, including representatives from regulatory authorities. The invited experts are well-recognized academic leaders in geriatrics, oncology, cardiology, pulmonology and regulatory issues.
These consensus projects aimed to facilitate the future design and performance of clinical trials in the fields of cachexia and sarcopenia[44] They also generated recommendations for nutritional management.[45]

Journal[edit]

The Journal of Cachexia, Sarcopenia and Muscle (JCSM) published by Wiley-Blackwell is the official journal of SCWD.[46] It was created in 2010.[47] According to the Journal Citation Reports, the journal has a 2017 impact factor of 12.511. JCSM has seen an increase in citations and submissions in 2016.[48] It is ranked in the first 10 journals for all journals in the field of "medicine, general and internal.[49] Two daughter journals also exist: JCSM—Clinical Reports started in July 2016 and JCSM—Rapid Communications.

About muscle wasting, cachexia and sarcopenia[edit]

Cachexia is a major issue, especially in the elderly.[50] Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.[51] Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to poor quality of life and increased morbidity/mortality. Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia.[52] Sarcopenia and cachexia represent the major causes of muscle-wasting disorders. It has been known for millennia that muscle and fat wasting leads to poor outcomes, including deaths in chronic disease states.
It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance, which are also common features of the frailty syndrome.[53]
Cachexia and sarcopenia are both characterized by an important muscle dysfunction and weakness[54] that lead to increased morbidity and mortality.[55] The cost of muscle wasting is high.[56]

References[edit]

  1. ^ What is cancer cachexia
  2. ^ Farkas, Jerneja; von Haehling, Stephan; Kalantar-Zadeh, Kamyar; Morley, John E.; Anker, Stefan D.; Lainscak, Mitja (7 December 2016). "Cachexia as a major public health problem: frequent, costly, and deadly". Journal of Cachexia, Sarcopenia and Muscle. 4 (3): 173–178. doi:10.1007/s13539-013-0105-y. ISSN 2190-5991. PMC 3774921. PMID 23539127.
  3. ^ McDaniels, Andrea K. "Groups seek better diagnosis and treatment of debilitating muscle loss in seniors". baltimoresun.com. Retrieved 9 February 2018.
  4. ^ Lok, Corie (10 December 2015). "Cachexia: The last illness". Nature. 528 (7581): 182–183. Bibcode:2015Natur.528..182L. doi:10.1038/528182a. PMID 26659165. S2CID 4469244.
  5. ^ Miller, Kelli. "What Is Cardiac Cachexia?". WebMD. Retrieved 2 May 2022.
  6. ^ "Cachexia". YouTube.
  7. ^ "Cachexia: Symptoms, Treatment, and Outlook". Medical News Today. Retrieved 24 January 2017.
  8. ^ von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (1 December 2016). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN 2190-6009. PMC 5114624. PMID 27891294.
  9. ^ "Curriculum vitae" (PDF).
  10. ^ "One of the nation' foremost authorities on geriatrics". Saint Louis University.
  11. ^ "The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA". Newswire.
  12. ^ "Society on sarcopenia, cachexia and wasting disorders". research.longfonds.nl. Retrieved 7 December 2016.
  13. ^ "Journal of Cachexia, Sarcopenia and Muscle - Society Information -". Journal of Cachexia, Sarcopenia and Muscle. Wiley Online Library. 2018. doi:10.1007/13539.2190-6009. hdl:10807/147340.
  14. ^ http://990s.foundationcenter.org/990_pdf_archive/800/800419218/800419218_201212_990.pdf [bare URL PDF]
  15. ^ "ESC Board". www.escardio.org. Retrieved 7 December 2016.
  16. ^ Coats, Andrew JS (2002). "Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath". International Journal of Cardiology. 85 (1): 133–139. doi:10.1016/s0167-5273(02)00242-5. PMID 12163218.
  17. ^ "This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know". Prevention. 27 September 2017. Retrieved 9 February 2018.
  18. ^ "Regulatory Recognition Key to Moving Forward on Sarcopenia: Interview with Dr. Bill Evans, GSK". 13 September 2012.
  19. ^ "Luigi Ferrucci named NIA scientific director | National Institute on Aging". Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  20. ^ "editorial". Clinical Nutrition.
  21. ^ "Obituary - Kenneth Fearon, professor of surgical oncology". HeraldScotland. 16 September 2016. Retrieved 7 December 2016.
  22. ^ Fearon, Kenneth; Strasser, Florian; Anker, Stefan D.; Bosaeus, Ingvar; Bruera, Eduardo; Fainsinger, Robin L.; Jatoi, Aminah; Loprinzi, Charles; MacDonald, Neil (1 May 2011). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–495. doi:10.1016/S1470-2045(10)70218-7. ISSN 1474-5488. PMID 21296615.
  23. ^ Anker, Markus S.; von Haehling, Stephan; Springer, Jochen; Banach, Maciej; Anker, Stefan D. (21 February 2013). "Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology". Archives of Medical Science. 9 (1): 166–171. doi:10.5114/aoms.2013.33356. ISSN 1734-1922. PMC 3598129. PMID 23515589.
  24. ^ "Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 43–128. 1 September 2010. doi:10.1007/s13539-010-0001-7. ISSN 2190-6009. PMC 3060650. PMID 22477519.
  25. ^ "5th Cachexia conference" (PDF). 5–8 December 2009. Archived from the original on 4 November 2011. Retrieved 1 July 2023.{{cite web}}: CS1 maint: unfit URL (link)
  26. ^ "Elderly Women Prefer Death to Suffering a Hip Fracture". HuffPost. 11 June 2014.
  27. ^ "Congress Report - 7th Cachexia Conference Kobe/Osaka, Japan, December 9−11, 2013 | Literature watch | Cancer Cachexia".
  28. ^ https://www.goedoc.uni-goettingen.de/goescholar/bitstream/handle/1/13727/jcsm12110.pdf?sequence=1 [bare URL PDF]
  29. ^ von Haehling, S; Anker, SD (22 February 2016). "The times they are a-changin': the Cachexia Conference goes annual". Journal of Cachexia, Sarcopenia and Muscle. 7 (1): 3–4. doi:10.1002/jcsm.12110. PMC 4771211. PMID 27066313.
  30. ^ "牡丹江市矿山设备经销部". cancercachexia2016.
  31. ^ "SINU – Società Italiana di Nutrizione Umana" (PDF).
  32. ^ von Haehling, Stephan; Anker, Stefan D. (1 September 2010). "Cachexia as a major underestimated and unmet medical need: facts and numbers". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 1–5. doi:10.1007/s13539-010-0002-6. ISSN 2190-6009. PMC 3060651. PMID 21475699.
  33. ^ Group, Helsinn. "Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung /PR Newswire UK/". www.prnewswire.co.uk. Retrieved 8 December 2016.
  34. ^ "Lundbeckfond Ventures ' MID-STAGE CLINICAL STUDY OF WASTING DISEASE THERAPEUTIC MT-102 SHOWS REVERSAL OF CANCER-RELATED WASTING". www.lundbeckfonden.com. Retrieved 12 December 2016.
  35. ^ "6th Cachexia Conference: Lisa Niemi-Swayze Slated as Keynote Speaker at SCWD Charity Dinner". www.newswire.com. Retrieved 7 December 2016.
  36. ^ "Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011 (Part 2)". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 51–68. 31 January 2012. doi:10.1007/s13539-012-0056-8. ISSN 2190-5991. PMC 3302985. PMID 22460563.
  37. ^ Ebner, Nicole; Werner, Claudia G.; Doehner, Wolfram; Anker, Stefan D.; Haehling, Stephan von (2 March 2012). "Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 45–50. doi:10.1007/s13539-012-0061-y. ISSN 2190-5991. PMC 3302986. PMID 22460618.
  38. ^ Morley, John E.; Abbatecola, Angela Marie; Argiles, Josep M.; Baracos, Vickie; Bauer, Juergen; Bhasin, Shalender; Cederholm, Tommy; Coats, Andrew J. Stewart; Cummings, Steven R. (1 July 2011). "Sarcopenia with limited mobility: an international consensus". Journal of the American Medical Directors Association. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. ISSN 1538-9375. PMC 5100674. PMID 21640657.
  39. ^ Evans, William J.; Morley, John E.; Argilés, Josep; Bales, Connie; Baracos, Vickie; Guttridge, Denis; Jatoi, Aminah; Kalantar-Zadeh, Kamyar; Lochs, Herbert (1 December 2008). "Cachexia: a new definition". Clinical Nutrition. 27 (6): 793–799. doi:10.1016/j.clnu.2008.06.013. ISSN 1532-1983. PMID 18718696. S2CID 206821612.
  40. ^ Advances in Food and Nutrition Research. Academic Press. 30 January 2014. ISBN 9780128003688.
  41. ^ morley, john (2011). "Sarcopenia With Limited Mobility: An International Consensus". Journal of the American Medical Directors Association. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. PMC 5100674. PMID 21640657.
  42. ^ Argilés, Josep M.; López-Soriano, Francisco J.; Toledo, Míriam; Betancourt, Angelica; Serpe, Roberto; Busquets, Sílvia (8 December 2016). "The cachexia score (CASCO): a new tool for staging cachectic cancer patients". Journal of Cachexia, Sarcopenia and Muscle. 2 (2): 87–93. doi:10.1007/s13539-011-0027-5. ISSN 2190-5991. PMC 3117995. PMID 21766054.
  43. ^ Morley, John E.; Argiles, Josep M.; Evans, William J.; Bhasin, Shalender; Cella, David; Deutz, Nicolaas E. P.; Doehner, Wolfram; Fearon, Ken C. H.; Ferrucci, Luigi (1 July 2010). "Nutritional recommendations for the management of sarcopenia". Journal of the American Medical Directors Association. 11 (6): 391–396. doi:10.1016/j.jamda.2010.04.014. ISSN 1538-9375. PMC 4623318. PMID 20627179.
  44. ^ Definition of Sarcopenia
  45. ^ Watson, Ronald Ross; Preedy, Victor R. (1 January 2013). Bioactive Food as Dietary Interventions for the Aging Population. Academic Press. ISBN 9780123971555.
  46. ^ Wiley-Blackwell online library
  47. ^ von Haehling, Stephan; Anker, Stefan D. (18 November 2018). "Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018". Journal of Cachexia, Sarcopenia and Muscle. 9 (6): 1021–1022. doi:10.1002/jcsm.12366. ISSN 2190-5991. PMC 6240749. PMID 30450844.
  48. ^ Journal of Cachexia, Sarcopenia and muscle
  49. ^ von Haehling, Stephan; Anker, Stefan D. (1 September 2015). "Moving on up: the Journal of Cachexia, Sarcopenia and Muscle". Journal of Cachexia, Sarcopenia and Muscle. 6 (3): 193–196. doi:10.1002/jcsm.12064. ISSN 2190-6009. PMC 4575549. PMID 26401464.
  50. ^ Mantovani, Giovanni (2006). Cachexia and Wasting: A Modern Approach. Milan: Springer. ISBN 978-8847004719.
  51. ^ Anker, Stefan D.; Morley, John E (1 December 2015). "Cachexia: a nutritional syndrome?". Journal of Cachexia, Sarcopenia and Muscle. 6 (4): 269–271. doi:10.1002/jcsm.12088. ISSN 2190-6009. PMC 4670732. PMID 26675043.
  52. ^ Evans, William J. (1 April 2010). "Skeletal muscle loss: cachexia, sarcopenia, and inactivity". The American Journal of Clinical Nutrition. 91 (4): 1123S–1127S. doi:10.3945/ajcn.2010.28608A. ISSN 0002-9165. PMID 20164314.
  53. ^ Morley, John E. (26 September 2016). "Frailty and sarcopenia in elderly". Wiener Klinische Wochenschrift. 128 (Suppl 7): 439–445. doi:10.1007/s00508-016-1087-5. ISSN 1613-7671. PMID 27670855. S2CID 20112072.
  54. ^ "Patients Suffering From Cachexia Need Nutritional Support". Cure Today. Retrieved 9 February 2018.
  55. ^ von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (1 December 2016). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN 2190-6009. PMC 5114624. PMID 27891294.
  56. ^ Green, Brent (6 December 2011). "Follow The Boomer Money: End Of Sarcopenia, Compression Of Morbidity". The Huffington Post. Retrieved 7 December 2016.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Society_on_Sarcopenia,_Cachexia_and_Wasting_Disorders&oldid=1210967567"